Expert Scientist

Masoumeh Es-haghi, PhD

Masoumeh started her research activities in 2006 with her master’s thesis on in vitro
production and molecular studies characterizing the preimplantation embryo and
received a Ph.D. in biotechnology. She has multiple years of experience in
understanding the stemness and migratory potential of primordial germ cells for next-
generation genetic engineering. In 2017, she pursued her
research career as a Postdoctoral Research Fellow in Eastern and Northern Europe
focusing on translational nanomedicine and biomarker discovery for assisted
reproductive technologies, exosome engineering of recombinant fusion proteins for
gene delivery, and immune microenvironmental studies of solid tumors resulting in a
patent and an innovation.
After 15 years of a life dedicated to science, she joined CCI to work with the HGEL team
toward more discoveries and advanced therapies for translational cancer medicine that
will improve patients’ life expectancy.

Elahe Kamali Ghahe, PhD

Elahe (she/her) is a Ph.D. in Molecular Genetics. She is passionate about using gene editing platforms to advance adoptive cell therapies. She relocated to the US for her post-doctoral training at Yale School of Medicine to explore the cell biology of CAR signaling and improve the CAR-T efficacy using genome editing. Elahe joined the Herbst-Nowrouzi lab in 2023 to evaluate the delivery of gene editing cargos using Lipid Nanoparticle, aiming to develop robust and reliable cell products for future development of cancer immunotherapy. Outside of her research, she enjoys traveling, cycling, watching movies, and spending time with family and friends.

Soon-Keat Ooi, PhD

Soon-Keat (he/him) joined the CCI community at Penn when he became the first postdoc at the
Herbst-Nowrouzi Lab in June 2022. In the lab, Soon-Keat seeks to apply his molecular biology
and biochemistry insight to contribute to the ongoing effort in improving and innovating current
immune cell-based cancer therapies. Collaborating with colleagues across the Penn campus,
Soon-Keat currently focuses his work on the optimization of methods widely used to assess the
activity and specificity of CRISPR/Cas-based genome editing enzymes in human blood cells.
Soon-Keat received his Bachelor of Science degree with a major in Genetics from the National
University of Malaysia, where he worked in the lab of Sheila Nathan to conduct undergraduate
research and, subsequently, remained in the same lab to further his research on dissecting the
virulence mechanism of Burkholderia pseudomallei (the causative agent of melioidosis) using
Caenorhabditis elegans as the animal host model. To broaden his research expertise, Soon-
Keat later attended the Graduate School of The Stowers Institute for Medical Research. For
Ph.D. training, Soon-Keat was co-mentored by Joan W. Conaway and Ronald C. Conaway, on
research aimed at delineating the biochemical mechanism underlying the exquisite regulation of
several human chromatin remodeling and DNA repair enzymes -- INO80, ALC1, and PARP1.
There, Soon-Keat not only acquired extensive protein biochemistry and enzymology training
from Joan and Ronald but also got inspired to translate his knowledge to help develop impactful
biotherapeutics that can surmount debilitating human diseases.
A Chinese born in Malaysia, Soon-Keat is well-versed in several languages and is frequently
taking advantage of that to mingle with people, both casually and intellectually. Outside the lab,
you will find Soon-Keat relaxing and reading scientific literature at home, intensely
playing/training badminton games, and exploring new cuisines in the city.

Fengjuan Jane Zhang, PhD

Fengjuan (Jane) majored in bioinformatics and obtained her Ph.D. degree in June 2019 from the
Shanghai Institute of Biochemistry and Cell Biology (SIBCB), Chinese Academy of Sciences (CAS). During
her Ph.D. study in Dr. Ligang Wu's lab, she focused on the profiles and functions of small non-coding
RNAs (sncRNAs) in mammalian spermatogenesis and oogenesis by using high-throughput sequencing
methods such as small RNA-seq, polyA+ RNA-seq, and CLIP-seq. She investigated the rapid evolution of a
unique X-linked miRNA family, named spermiRs, that is predominantly expressed in the early meiotic
phases, and demonstrated an intriguing co-evolution between spermiR and its targets in mammalian
spermatogenesis.
During her two-year postdoc training in Dr. Ligang Wu's lab, she collaborated with colleagues
and developed a method that could simultaneously profile mRNAs and small non-coding RNAs in a single
cell. Using this method, they first uncovered the essential role of PIWI/piRNAs in female germ cell
generation, using the golden hamster as an animal model. They also used the method to investigate
how proliferating cells use miRNAs and alternative polyadenylation to orchestrate mRNA levels during
the cell cycle.
In January 2022, she joined Dr. Bin Tian's lab as a postdoc. During her postdoc training in Tian
lab, she learnt the knowledge and computational skills to identify novel poly-A sites using 3’READS+ and
quantify poly-A site usage changes to evaluate alternative polyadenylation (APA) regulation.
In March 2023, she joined the Center of Cellular Immunotherapy as a postdoc, under the
supervision of Drs. Herbst-Nowrouzi and Fraietta, and began her science journey in the immunotherapy
field. Outside of work, Jane enjoys playing ping pong and tennis, swimming, and hiking.

Gozde Sir Karakus, MSc

Gozde obtained her Bachelor’s degree in Biology from Ege University in Izmir, Turkey in 2012. She further pursued her studies and earned a Master of Science degree in Stem Cell Biology.

Driven by her interest in cellular therapy, Gozde gained experience as a Product Specialist at the Acıbadem Healthcare Labcell Laboratory in Istanbul, Turkey. In this role, she focused on developing various cellular immunotherapeutic products in a GMP (Good Manufacturing Practice) environment for direct clinical application.

Gozde then joined HGEL as a Research Specialist, where she took lead in projects related to primary cell enrichment and scale-up processes. Her main objective is to enhance the clinical manufacturing of genetically engineered cell-based products by implementing novel strategies and innovative technologies.

Rujul Jagdish Deolikar, BSc

Rujul is a Master's student in Biotechnology at the University of Pennsylvania. He has an
undergraduate degree in Biotechnology from Amity University, Mumbai, and further explored
his scientific interests in a hematopoietic stem cell-related project using Drosophila as a model
system at the Advanced Centre for Treatment, Research and Education in Cancer, Navi
Mumbai, for his Bachelor's Dissertation.
His interests in research include immunology, hematology, cancer biology and of course, the
field of cell and gene therapies, with the help of which he wishes to utilize his training to
formulate safe, effective, and patient-specific products to treat disorders like cancer without
the use of potentially toxic therapies. He is very excited about the future of the gene therapy
field.
Presently, he is working as a Student Worker at the Human Genome Editing Lab to work on
enhancement of the Hematopoietic Stem Progenitor Cell population by CRISPR/Cas9-mediated
genetic engineering combined with the establishment of defined functional assay as a readout.

Qihua Ashley Yang, BSc